Proning

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

Retrieved on: 
Tuesday, January 3, 2023
Medical school, F2, Fatty liver disease, Fibrosis, Patient, CCL24, PSC, Communication, ELF, Optimism, NAFLD, Primary sclerosing cholangitis, Systemic scleroderma, Institute of Liver and Biliary Sciences, Sheila Sherlock, Cirrhosis, SC, University College London, Marketing, Division, Nature, Faculty, Safety, Inflammation, Clinical trial, CMMB, UCL, Scleroderma, Icahn School of Medicine at Mount Sinai, Intracellular digestion, Therapy, Principal, TEL, Gastroenterology, F3, Proning, Doctor of Philosophy, Risk, Pharmacokinetics, Non-alcoholic fatty liver disease, Liver, University College London Hospitals NHS Foundation Trust, Research, NASH, Biomarker, Hepatology, Medical imaging, Pharmaceutical industry, Vaccine, Medicine, COVID, MD

TEL AVIV, Israel, Jan. 3, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported top-line results from its Phase 2a trial assessing CM-101, its first-in-class CCL24-neutralizing monoclonal antibody, in non-alcoholic steatohepatitis (NASH) patients. The trial met its primary endpoint of safety and tolerability, and CM-101 achieved reductions in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments measured at baseline and at week 20.

Key Points: 
  • The randomized, placebo-controlled trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo.
  • Dr. Pfost continued, "This is the third clinical trial in patients demonstrating the activity of CM-101 as measured by fibro-inflammatory biomarkers and physiological assessments.
  • A Phase 2 liver fibrosis biomarker study in NASH patients was recently completed and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing.
  • Chemomab expects to begin enrolling patients in a Phase 2 trial in systemic sclerosis early in 2023.

Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury

Retrieved on: 
Tuesday, December 13, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Fund, NIH, Probability, Innovation, Research and development, Development, IND, Partnership, Research, PCI, Patient, Proning, Inc., HIV disease progression rates, CMC, Investment, University, NOX2, ALI, Organization, Pharmaceutical industry, Management

Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (PXV Fund).

Key Points: 
  • Peroxitech Inc., an emerging biopharmaceutical company developing a novel peptide for treating acute lung injury (ALI), announced the successful completion of a Series A financing round of $25 million led by the Perceptive Xontogeny Venture Fund (PXV Fund).
  • Peroxitechs lead asset mechanism leverages the discovery of a novel signaling pathway, NOX2, related to the oxidative injury cascade, which has demonstrated broad protection and rescue in several preclinical models.
  • The Companys novel peptide shows it can protect cells from injury and enables injured ones to recover to near normal levels.
  • Peroxitech Inc. is a privately held biopharmaceutical company focused on the development and commercialization of a novel therapeutic for treatment of acute lung injury.

Disarming the immune system's lethal lung response

Retrieved on: 
Friday, September 23, 2022
Neuroscience, Inflammation, COVID-19, Ageing, Biomedical Research, Sepsis, Neutrophil, Nobel Prize, Neurodegeneration, Mouse, Environment, Infection, Signal transduction, Cancer, Cold, Blood, Protein, Weapon, Student, Hyperkinesia, Cold Spring Harbor Laboratory, Cell, Laboratory, SPRING, Tissue, Transfusion-related acute lung injury, Research, CSHL, Multimedia, Proning, Education, Disease, Death, PTP, Pharmaceutical industry, Vaccine, PTP1B

Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks.

Key Points: 
  • Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks.
  • If severe enough, acute lung injuries can lead to acute respiratory distress syndrome (ARDS), the leading cause of death due to COVID-19.
  • Nicholas Tonks , Caryl Boies professor of cancer research at Cold Spring Harbor Laboratory (CSHL), and his team have found a drug candidate that can prevent lethal lung inflammation in mice by inhibiting a protein called PTP1B.
  • "When you think about COVID-19, acute lung injury and ARDS underlie the fatal aspects of the disease," Tonks says.

MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Retrieved on: 
Thursday, June 30, 2022
FDA, Patient, Code, Amyotrophic lateral sclerosis, MS, Program, Proning, Biomedical Advanced Research and Development Authority, IPF, Nasdaq, MIF, GLOBE, NAFLD, Chlorine, CIPN, Failure, Multiple sclerosis, ALI, United States Department of Health and Human Services, Intellectual property, U.S. Securities and Exchange Commission, ALS, Annual report, PDE4, Redirect, Tokyo Stock Exchange, Development, Glioblastoma, MCM, Chemotherapy-induced peripheral neuropathy, Idiopathic pulmonary fibrosis, Risk, Acute respiratory distress syndrome, Security (finance), Drive, Private Securities Litigation Reform Act, Radiation, Human services, BARDA, NASDAQ, Non-alcoholic fatty liver disease, Form 10-K, DCM, Neurodegeneration, Form 8-K, Pharmaceutical industry, Research

Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Key Points: 
  • Department of Health and Human Services, to repurpose MN-166 (ibudilast) as a potential medical countermeasure (MCM) against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
  • MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.
  • MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications

Retrieved on: 
Tuesday, June 14, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Hospital, IPF, Data, Death, PRTC, Șaeș, Fibrosis, Time, Pneumonia, Company, AES, COVID, Interstitial lung disease, Headache, Research, Keck School of Medicine of USC, Safety, Fatigue, Pirfenidone, LSE, Annual report, Degenerative disease, Long COVID, Nausea, Cancer, Inflammation, Environment, AE, Dizziness, Therapy, University, Daphne, Risk, FDA, Proning, COVID-19, Patient, Private Securities Litigation Reform Act, U.S. FDA, Medicine, Natural history, Incidence, Breast cancer–related regulator of tp53, SEC, Twitter, Population, Survivor, Drug development, Rash, Intention, Form 6-K, PureTech Health, Principal, Idiopathic pulmonary fibrosis, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in patients with post-acute Long COVID with respiratory complications.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced results from a Phase 2 study of LYT-100-COV (deupirfenidone) in patients with post-acute Long COVID with respiratory complications.
  • The global, double-blind, randomized, placebo-controlled study is one of few to complete in patients with post-acute COVID.
  • The study enrolled 177 patients averaging 55 years of age who experienced continued respiratory complications following hospitalization for acute COVID-19 infection that required treatment with supplemental oxygen.
  • The primary efficacy endpoint was a three-month change from baseline compared to placebo on the six-minute walk test (6MWT) distance.

MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

Retrieved on: 
Wednesday, June 8, 2022
Soft tissue injury, Oxygen, IPF, Death, Coronavirus, Pneumonia, Intellectual property, NIAID, DCM, Acute respiratory distress syndrome, CIPN, Form 10-K, Form 8-K, Annual report, Neurodegeneration, NAFLD, Glioblastoma, Tokyo Stock Exchange, Security (finance), U.S. Securities and Exchange Commission, Inflammation, Amyotrophic lateral sclerosis, Female, Failure, Non-alcoholic fatty liver disease, Vaccine, MIF, FDA, Proning, Patient, Infection, MS, Risk, Chemotherapy-induced peripheral neuropathy, GLOBE, ALS, Code, Private Securities Litigation Reform Act, COVID-19, Atmosphere, NASDAQ, Courage, Male, Nasdaq, MD, Clinical trial, Virus, Multiple sclerosis, Oxygen saturation (medicine), MPH, PDE4, Carbon, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Medical imaging, Doctor of Philosophy

The trial achieved statistical significance for one of the co-primary endpoints, the proportion of subjects free of respiratory failure.

Key Points: 
  • The trial achieved statistical significance for one of the co-primary endpoints, the proportion of subjects free of respiratory failure.
  • The clinical trial enrolled 36 subjects and randomized 34 subjects including 17 subjects in the MN-166 (ibudilast) group and 17 subjects in the placebo group.
  • Male and female participants (mean age = 60 years) were equally represented in MN-166 (ibudilast) and placebo treatment groups.
  • In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).

BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, May 16, 2022
Senior, Medical Affairs Bureau, MHSC, ISCT, American Academy, Exo, International Society, Master of Science, ISEV, Drug development, Research, VP, NEW, Hospital, Doctor of Philosophy, Clinical, Company, Webcast, Patient, NASDAQ, ADV, Therapy, Episcopal conference, MPH, Adult, Antal, Neurology, Neurodegeneration, Cerebrospinal fluid, Conference, Conference call, Neuroprotection, Congress, Biomarker, HIV disease progression rates, Proning, Division, Massachusetts General Hospital, Harvard Medical School, Muscular dystrophy, Growth, Development, ALS, Management, Pharmaceutical industry, Medical device, Online gambling, MD

NEW YORK, May 16, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • The presentation was delivered by Dr.Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.
  • Announced upcoming presentations at the ALS Drug Development Summit (May 25, 2022) and the ISEV 2022 Annual Meeting (May 26, 2022).
  • Presented a corporate and Phase 3 ALS clinical overview at the 12thAnnual California ALS Research Summit on January 27, 2022 by Ralph Kern MD MHSc, President and Chief Medical Officer Brainstorm Cell Therapeutics.
  • Net loss per share for the three months ended March 31, 2022, and 2021 was $0.15 and $0.19 respectively.

BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting

Retrieved on: 
Wednesday, May 4, 2022
COVID-19, Amyotrophic lateral sclerosis, California Institute for Regenerative Medicine, Immunomodulation, M1, National, Senior, EMA, TGM2, NASDAQ, Multiple sclerosis, European Medicines Agency, Company, Proning, MS, Annual report, Food, Safety, Cell, Regenerative medicine, Poster, CA, Exo, ISCT, Gene, Neurodegeneration, Clinical trial, NTFS, FDA, Brainstorm, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene expression, Orphan drug, MD, Medical Affairs Bureau, Exosome, MHSC, Phrase, Microsoft, IL10, Research, International Society, CIRM, Nave, Silk, Pharmaceutical industry, Vaccine, ALS

NEW YORK, May 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs," at the International Society of  Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA. The poster will be presented by Dr. Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.

Key Points: 
  • The poster will be presented by Dr. Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.
  • Exo MSC-NTF treatment led to statistically significant 6.4 and 3.3-fold reductions in the secretion and transcription (gene expression) of the pro-inflammatory cytokine MCP-1.
  • "These compelling preclinical data provide important insights into Exo MSC-NTF's mechanism of action," said Ralph Kern, MD MHSc, President and Chief Medical Officer of BrainStorm.
  • BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm Announces Upcoming Scientific Conference Presentations

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, Amyotrophic lateral sclerosis, California Institute for Regenerative Medicine, National, Senior, EMA, Drug development, NASDAQ, Multiple sclerosis, European Medicines Agency, Company, Proning, MS, Biomarker, Food, Safety, Annual report, Regenerative medicine, CSF, Exo, ISCT, Neurodegeneration, Clinical trial, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Orphan drug, Transfusion-related acute lung injury, ISEV, Medical Affairs Bureau, Phrase, CIRM, Research, Pharmaceutical industry, Brainstorm, ALS

NEW YORK, May 3, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022.  New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (May 4 to 7 in San Francisco, CA) and at the ISEV 2022 Annual Meeting (May 25 to 29 in Lyon, France).   An analysis of CSF biomarkers from the NurOwn® Phase 3 trial will be presented at the ALS Drug Development Summit (May 24 to 26 in Boston, MA).

Key Points: 
  • NEW YORK, May 3, 2022 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022.
  • An analysis of CSF biomarkers from the NurOwn Phase 3 trial will be presented at the ALS Drug Development Summit (May 24 to 26 in Boston, MA).
  • BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury

Retrieved on: 
Tuesday, March 22, 2022
Company, Cell, Therapy, Risk, Form 10-K, Private Securities Litigation Reform Act, ACE2, Transfusion-related acute lung injury, Lung, Marketing, Growth, Annual report, ADS, HK, Patient, Proning, Hypertension, U.S. Securities and Exchange Commission, Heart, Jean-Louis Vincent, Security (finance), MD, Safety, Technology, Infant respiratory distress syndrome, Lucinactant, Inflammation, WINT, Cardiogenic shock, COVID-19, Instability, GLOBE, Respiratory distress syndrome, Extracorporeal membrane oxygenation, ECMO, FDA, Acute respiratory distress syndrome, RDS, Angiotensin-converting enzyme 2, Protein, Blood, Respiratory system, Infection, Pharmaceutical industry, Vaccine

Surfactant deficiency is known to contribute to the pathophysiology of ARDS, respiratory failure, and lung injury in patients on mechanical ventilation.

Key Points: 
  • Surfactant deficiency is known to contribute to the pathophysiology of ARDS, respiratory failure, and lung injury in patients on mechanical ventilation.
  • The Phase 2 trial was designed to assess feasibility, safety, and tolerability of administration of reconstituted lyophilized lucinactant in these critically ill patients.
  • The multicenter, single-arm study enrolled 20 critically ill patients who were intubated and on mechanical ventilation due to severe COVID-19 associated ARDS.
  • Patients received lucinactant as a liquid via the endotracheal tube assessing safety and tolerability of the administration procedure and of the drug.